Clinical trials: Body Weight Control
Obesity, Intra-Abdominal Fat
Effect of a Probiotic on Visceral Fat Accumulation
The study's main objective is to investigate if an extract containing the probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) has a positive effect on the accumulation of abdominal visceral fat in people with…
- Conditions
- Obesity, Intra-Abdominal Fat, Subcutaneous Fat, Abdominal
- Trial name
- BIFFAT (NCT02921217)
- Testing
- Active Probiotic, Inactivated probiotic, Control
- Where
- Spain
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Biopolis S.L.
Overweight, Obese
AZD7687 Multiple Ascending Dose Study
The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD7687 following multiple ascending dose administrations in in overweight to obese but otherwise healthy male subjects
- Trial name
- NCT01119352
- Testing
- AZD7687
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy, Overweight and Obese Adults
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.
- Trial name
- NCT07307274
- Testing
- SYNT101
- Where
- Australia
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Syntis Bio
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers
This study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07801313
- Testing
- MWN105
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Gastrointestinal Microbiome (Focus), Gastrointestinal Symptoms
The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals With Excessive Body Weight
The study is a single-center, randomized, double-blind, placebo-controlled study in middle-aged to elderly adults with excessive body weight. The study includes an 8-week intervention period followed by a 2-week follow-up period.
- Trial name
- myBIOM (NCT07453823)
- Testing
- Synbiotic
- Where
- Ireland
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Chr Hansen - part of Novonesis
Obesity
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112
1. Study Objective: The objective of this phase 1 clinical trial is to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and food effect of HSG4112 after oral administration in healthy male…
- Trial name
- NCT04732988
- Testing
- HSG4112
- Where
- 2 sites in South Korea
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Glaceum
Obesity
EMPOWER Clinical Trial: Vagal Blocking for Obesity Control
This is a randomized multi-center study being done to measure the ability of a new medical device, Maestro System, to safely reduce body weight over five years in people who are considered obese.
- Trial name
- EMPOWER (NCT00521079)
- Testing
- Therapy ON, Therapy OFF
- Where
- 15 sites in United States, Australia
- Volunteers
- 294 people
- Sponsor
- ReShape Lifesciences
Obesity, Overweight
Taldefgrobep Alfa in Adults With Overweight and Obesity
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
- Trial name
- NCT07281495
- Testing
- Taldefgrobep Alfa
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- Biohaven Therapeutics Ltd.
Obesity
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
This is a 56-week randomized, open-label, controlled study evaluating the efficacy and safety of the HDM1005 compared to tirzepatide in adults with obesity but without diabetes.
- Trial name
- NCT07521631
- Testing
- HDM1005 dose level 1, HDM1005 dose level 2, HDM1005 dose level 3
- Where
- China
- Volunteers
- 372 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Weight, Body
Effect of Synbiotic L. Fermentum Strains on Body Fat Mass
In this placebo-controlled trial the effect of a synbiotic consisting of three different strains of Lactobacillus fermentum and acacia gum (gum arabic) was compared with a probiotic formulation containing identical strains on…
- Trial name
- NCT05405205
- Testing
- synbiotic, probiotic
- Where
- Germany
- Volunteers
- 180 people
- Sponsor
- Slimbiotics GmbH
Clinical Pharmacology
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight
BAY 63-2521 is intended to be used for a disease that affects the blood flow through the lungs. Renal impairment is a common condition in patients with this disease.
- Trial name
- NCT04366622
- Testing
- Riociguat (Adempas, BAY 63-2521)
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Weight Loss, Appetite Modulation (Focus of Study)
Safety and Efficacy of IQP-AK-102 in Reducing Appetite
The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several studies demonstrating their efficacy, we are conducting this study to look into the efficacy and safety of this novel combination of…
- Trial name
- NCT02041754
- Testing
- IQP-AK-102
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity, Overweight
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide.
- Trial name
- RENEW 1 (NCT07220642)
- Testing
- Cagrilintide
- Where
- 40 sites in United States, Argentina and 8 more
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Obesity
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects
This clinical trial is the first-in-human study of NO-13065. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses and food effect of NO-13065 in healthy and obese…
- Trial name
- NCT04838639
- Testing
- NO-13065
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Factory, Inc.
Obesity
ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity
The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.
- Trial name
- NCT04890873
- Testing
- ERX1000
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- ERX Pharmaceuticals
Overweight, Obesity
A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression
This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks.
- Conditions
- Overweight, Obesity, Blood Sugar Regulation, Appetite Suppression
- Trial name
- NCT07889570
- Testing
- Evolv GLP-1 Group, Control Group
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Evolv
Obesity, Obesity, Abdominal
Vestibular Stimulation to Trigger Adipose Loss Clinical Trial
There is an ongoing and worsening problem with obesity in the developed, and much of the developing world. Although it has long been realized that Western diets that are rich in sugar and fat play an important role in this, it…
- Conditions
- Obesity, Obesity, Abdominal, Metabolic Syndrome, Weight Loss
- Trial name
- VeSTAL (NCT03138369)
- Testing
- Vestibular nerve stimulator
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Neurovalens Ltd.
Depression, Depressive Disorder
Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management
The primary aims of the proposed research are to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for the…
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Episode
- Trial name
- NCT05351866
- Testing
- CBT-based mobile intervention for depression, Mobile control with education about depression
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Limbix Health, Inc.
Type 2 Diabetes Mellitus (T2DM), Food Effect
Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes
The goal of this intervention study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of MKP10241 in obese participants with and without T2DM in 3 parts.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Food Effect, Safety and Tolerability, Obesity
- Trial name
- NCT07098663
- Testing
- MKP10241
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Mankind Pharma Limited
Cachexia
Regimen for the Treatment of Cachexia in Subjects With NSCLC
Cachexia is a presentation of a chronic manifestation of acute metabolic stress, a hypercatabolic nutritional state in which the normal fat and protein sparing mechanisms are not functioning and increased nutrition is not…
- Trial name
- VT-122 (NCT00527319)
- Testing
- VT-122 low dose, VT-122 high dose
- Where
- 8 sites in United States, India
- Volunteers
- 37 people
- Sponsor
- Vicus Therapeutics